# Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency

> **NCT01958281** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 38 (actual)

## Conditions studied

- HCV Infection

## Interventions

- **DRUG:** SOF
- **DRUG:** RBV
- **DRUG:** LDV/SOF

## Key facts

- **NCT ID:** NCT01958281
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-07
- **Primary completion:** 2017-07-18
- **Final completion:** 2017-10-19
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2018-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01958281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01958281, "Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01958281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*